|Original language||English (US)|
|Number of pages||2|
|Journal||JAMA - Journal of the American Medical Association|
|State||Published - Mar 17 2020|
Bibliographical noteFunding Information:
Author Affiliations: Washington University School of Medicine in St Louis, St Louis, Missouri (Goldberg); Esperion Therapeutics Inc, Ann Arbor, Michigan (Hanselman); Oregon Health & Science University, Portland (Duell). Corresponding Author: Anne Carol Goldberg, MD, Washington University School of Medicine in St Louis, 660 South Euclid, Campus Box 8127, St Louis, MO 63110 (firstname.lastname@example.org). Conflict of Interest Disclosures: Dr Goldberg reported receiving grants from Amgen, Amarin, Pfizer, Regeneron, Sanofi, Ionis, Novartis, and Merck and serving as a consultant for Esperion, Novartis, Akcea, Optum RX, 23andMe, Sanofi/Regeneron, and Merck. Mr Hanselman reported receiving salary, personal fees, stock, and stock options from Esperion. Dr Duell reported receiving institutional research grants from Retrophin, Regeneron, and Regenxbio and serving as a consultant for Akcea, AstraZeneca, Esperion, Retrophin, Regeneron, and Regenxbio.
PubMed: MeSH publication types